| 克拉生坦 |
| |
| 引用本文： | 吕超君,谭初兵,周植星,张大同,徐为人.克拉生坦[J].医学教育探索,2011,26(1):68-71. |
| |
| 作者姓名： | 吕超君 谭初兵 周植星 张大同 徐为人 |
| |
| 作者单位： | 天津药物研究院 天津市新药设计与发现重点实验室, 天津 300193；天津中医药大学 中药学院, 天津 300193;天津药物研究院 天津市新药设计与发现重点实验室, 天津 300193;山东轻工业学院 化工学院, 山东 济南 250353;天津药物研究院 天津市新药设计与发现重点实验室, 天津 300193 |
| |
| 摘 要： | 摘 要 脑血管痉挛（cerebral vasospasm, CVS）是蛛网膜下腔出血（subarachnoid hemorrhage, SAH）最常见的高危并发症之一, 是SAH患者致死和致残的主要原因。有证据表明, 内皮素信号系统在SAH后CVS和迟发性脑缺血损伤的病理生理过程中起重要作用, 因而内皮素受体拮抗剂在CVS治疗中的意义备受关注。克拉生坦（Clazosentan）是一种选择性内皮素受体拮抗剂, 动物实验和临床试验都表明其可有效缓解SAH引发的CVS, 故有望成为脑血管痉挛的新型治疗药物。
|
| 关 键 词： | 克拉生坦 蛛网膜下腔出血 脑血管痉挛 内皮素受体 内皮素受体拮抗剂 |
Clazosentan |
| |
| LV Chao-jun,TAN Chu-bing,ZHOU Zhi-xing,ZHANG Da-tong and XU Wei-ren.Clazosentan[J].Researches in Medical Education,2011,26(1):68-71. |
| |
| Authors: | LV Chao-jun TAN Chu-bing ZHOU Zhi-xing ZHANG Da-tong and XU Wei-ren |
| |
| Institution: | Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China; School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China;School of Chemical Engineering, Shandong Institute of Light Industry, Jinan 250353, China;Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China |
| |
| Abstract: | Abstract: Cerebral vasospasm (CVS) is one of the most common complications with high risk following subarachnoid hemorrhage (SAH), and a leading cause of death and disability in SAH patients. There are evidences shown that endothelin pathways play key roles in the CVS following SAH and late cerebral ischemic injury, thus the therapeutic significance of endothelin receptor antagonists in CVS attract widely attention. Clazosentan, a selective endothelin receptor antagonist, has been proved to be effective for SAH-induced CVS in animal experiments and clinical trials. It is expected to become a new drug for treatment of CVS. |
| |
| Keywords: | Clazosentan subarachnoid hemorrhage cerebral vasospasm endothelin receptor endothelin receptor antagonist |
|
| 点击此处可从《医学教育探索》浏览原始摘要信息 |
| 点击此处可从《医学教育探索》下载免费的PDF全文 |
|
